Lymphoseek Approval Expanded to Pediatric Patients
The approval was based on data from a phase 2 trial that assessed Lymphoseek in pediatric patients with melanoma, RMS, or other solid tumors.
Oncology
FORTE Study Compares Multiple Regimens in Patients With Multiple Myeloma With Cytogenetic Abnormalities
Researchers sought to determine whether a combination carfilzomib-lenalidomide-dexamethasone induction and consolidation with ASCT would improve survival in patients with MM with cytogenetic abnormalities.
Carfilzomib-Based Consolidation Regimen May Be Inferior to ASCT in Patients With Multiple Myeloma
Researchers sought to determine whether carfilzomib-based consolidation and maintenance therapy regimen may yield similar outcomes to those seen with ASCT in patients with MM.
Clinical Challenge: Nonhealing Growth on Nose
A 92-year-old man is referred for evaluation and treatment of a nonhealing growth on his nose. Can you make the correct diagnosis?
Prostate Cancer ADT Not Linked to Greater Cardiovascular Mortality
Androgen deprivation therapy added to radiation therapy (RT) for unfavorable-risk prostate cancer is not associated with an increased risk for cardiovascular mortality compared with RT alone, even among patients with preexisting cardiovascular disease, a study found.
Romidepsin and Lenalidomide Combination Effective as Initial Therapy for Peripheral T-Cell Lymphoma
Researchers sought to determine whether a combination therapy of romidepsin and lenalidomide would be effective as initial therapy for patients with PTCL.
Penpulimab Shows Promise for Relapsed/Refractory Classic Hodgkin Lymphoma
Researchers sought to determine whether penpulimab would have efficacy and a low rate of serious AEs in patients with relapsed/refractory classic Hodgkin lymphoma.
Additional Tablet Strengths of Xpovio Now Available
The additional strengths are intended to increase patient compliance and reduce pill burden.
Accelerated Approval Granted to Truseltiq for Cholangiocarcinoma
Truseltiq is an orally administered, ATP-competitive, tyrosine kinase inhibitor of FGFR.
Lumakras Gets Accelerated Approval for KRAS G12C-Mutated NSCLC
The Food and Drug Administration (FDA) has granted accelerated approval to Lumakras (sotorasib) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least 1 prior systemic therapy. Sotorasib, an inhibitor of the RAS GTPase family, works by…
